SAN DIEGO—(BUSINESS WIRE)—
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:
—The BIOCOM Investor Conference 2008 on Tuesday, October 28, 2008, at 3:30 p.m. Pacific Time at the Hyatt Regency in San Diego. —BIO InvestorForum 2008 on Thursday, October 30, 2008, at 12:00 p.m. Pacific Time at The Palace Hotel in San Francisco.
Live webcasts of these presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for two weeks following the presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio of its four most advanced product candidates, including pimavanserin in Phase III for Parkinson's disease psychosis, a compound in Phase II for chronic pain and a compound in Phase I for glaucoma, both in collaboration with Allergan, and ACP-106 in IND-track development. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform and are directed at indications with large unmet medical needs. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Source: ACADIA Pharmaceuticals Inc.